Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

rate ("CER") basis, which is a Non GAAP measure, product sales were up 25%.

Product sales in the quarter benefited from higher ADDERALL XR® sales, in part due to significantly lower sales deductions following a lowering of the estimate of inventory in the US retail pipeline.

  • The strong product sales growth more than offset declines in 3TC® and ZEFFIX® royalties, both of which are now affected by the disagreement with GlaxoSmithKline ("GSK"), to give growth in total revenues of 24%, to $1,086 million in the quarter (Q3 2010: $874 million).


 

  • As expected, research and development ("R&D") was up 21% on a Non GAAP basis compared to Q3 2010, as we continue to invest in both early and late stage programs across our business to enable us to deliver future growth. On a US GAAP basis, R&D expenditure increased 2% compared to Q3 2010.


 

  • Non GAAP operating income was up 15% to $341 million (Q3 2010: $298 million). As expected, Non GAAP operating expenses increased at broadly the same rate as the increase in product sales compared to Q3 2010. This increase was due to increased investment in our R&D program and higher selling, general and administrative ("SG&A") expenditure as we absorb the operating costs of Advanced BioHealing Inc. ("ABH") and Movetis, neither of which were incurred in Q3 2010, in addition to supporting product launches and our continued growth.


 

Non GAAP diluted earnings per American Depositary Share ("ADS") were up 10% to $1.28 (Q3 2010: $1.16), due to the higher Non GAAP operating income, partially offset by higher Non GAAP Other Expenses.

  • On a US GAAP basis, operating income was up 64% to $255 million (Q3 2010: $156 million). Q3
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) provider ... provider of clinical research and data management services to ... its CRO Partnership Program, Clinovo expands ClinCapture , ... , “We have found Clinovo’s ClinCapture to exceed our ... is both user friendly and easy to deploy. The ...
(Date:11/26/2014)... 25, 2014 Global biostimulants market ... growing at an estimated CAGR of 12.5%. In ... food products with least ecological impacts, farmers are ... to boost crop yield more effectively & efficiently. ... can improve the return on investments. , Leading ...
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results,and ... 31, 2008., "We are currently enrolling or ... four exploring the use of REOLYSIN(R) as a ... combination with a variety of,chemotherapies, immune modulation and ...
... batch of bluetongue Bovilis BTV8 vaccine released to supply Northern ... ... Animal Health (NYSE: SGP ) released the first batch,of Bovilis ... company, combining after the acquisition in 2007 the,strength of Intervet and ...
... BOSTON, April 30 Today John C. Lechleiter,Ph.D., ... (NYSE: LLY ), provided,insight into the future ... that,key players, significant investments in the sector are ... Conference, a gathering of,policymakers, business leaders and academics, ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 First Quarter Results 2Oncolytics Biotech Inc. Announces 2008 First Quarter Results 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 4Oncolytics Biotech Inc. Announces 2008 First Quarter Results 5Oncolytics Biotech Inc. Announces 2008 First Quarter Results 6Oncolytics Biotech Inc. Announces 2008 First Quarter Results 7Oncolytics Biotech Inc. Announces 2008 First Quarter Results 8Oncolytics Biotech Inc. Announces 2008 First Quarter Results 9Oncolytics Biotech Inc. Announces 2008 First Quarter Results 10Oncolytics Biotech Inc. Announces 2008 First Quarter Results 11Oncolytics Biotech Inc. Announces 2008 First Quarter Results 12Oncolytics Biotech Inc. Announces 2008 First Quarter Results 13Oncolytics Biotech Inc. Announces 2008 First Quarter Results 14Oncolytics Biotech Inc. Announces 2008 First Quarter Results 15Oncolytics Biotech Inc. Announces 2008 First Quarter Results 16Oncolytics Biotech Inc. Announces 2008 First Quarter Results 17Oncolytics Biotech Inc. Announces 2008 First Quarter Results 18Oncolytics Biotech Inc. Announces 2008 First Quarter Results 19Oncolytics Biotech Inc. Announces 2008 First Quarter Results 20Oncolytics Biotech Inc. Announces 2008 First Quarter Results 21Oncolytics Biotech Inc. Announces 2008 First Quarter Results 22Oncolytics Biotech Inc. Announces 2008 First Quarter Results 23Oncolytics Biotech Inc. Announces 2008 First Quarter Results 24Oncolytics Biotech Inc. Announces 2008 First Quarter Results 25Oncolytics Biotech Inc. Announces 2008 First Quarter Results 26Oncolytics Biotech Inc. Announces 2008 First Quarter Results 27Oncolytics Biotech Inc. Announces 2008 First Quarter Results 28Oncolytics Biotech Inc. Announces 2008 First Quarter Results 29Oncolytics Biotech Inc. Announces 2008 First Quarter Results 30Oncolytics Biotech Inc. Announces 2008 First Quarter Results 31Oncolytics Biotech Inc. Announces 2008 First Quarter Results 32Oncolytics Biotech Inc. Announces 2008 First Quarter Results 33Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 2Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 3Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth 2
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... be used to produce an organic substrate for use in ... advantage that it can be recycled and is more economic ... , These are the findings of researchers at the ... in Ziordia (Navarre), have developed this substrate material. The product ...
... University of Manchester have created a new type of 'bio-gel' ... 3D, as published in the journal Advanced Materials (March 2006). ... from combinations of dipeptides (pairs of amino acids) to provide ... conditions. , Uniquely, the gel mimics the properties of cell ...
... of human DNA have different structures that are treated differently ... found in a study that could help lead to cancer ... issue of the journal Molecular Cell ?focuses on the ends ... time the cell divides, the telomeres shorten. When they become ...
Cached Biology News:New organic substrate 2Manchester scientists create new bio-gel for 3D cell culture 2DNA end caps may lead to cancer treatments, UT Southwestern researchers report 2
... System provides a simple, rapid and ... glutathione-S-transferase (GST) fusion proteins. Immobilized glutathione ... to isolate GST-tagged protein directly from ... either a manual (requires use of ...
... compact, versatile system that simultaneously harvests and ... microplates into a solid filter supports for ... gamma counter. The FilterMate is ideal for ... as cell proliferation, receptor binding, nucleic acid ...
... based screening project: , 384 ... 96 shape-diverse mixtures of 4 (5 uL each) , ... Individual compounds are dissolved in DMSO at ... Supplied in 5 96-well trays. Dilute library with ...
... Detection Kit (Catalog number SCR004) is a ... assessment of ES cell differentiation by the ... from CHEMICON are the monoclonal antibodies TRA-2-49 ... MAB4354), which permit the detection of Liver ...
Biology Products: